Philip Greenberg, M.D.

Philip Greenberg, M.D.

Institution: Fred Hutchinson Cancer Research Center

Project: Overcoming obstacles for cellular immunotherapy against lung cancer

Grant(s): Lung Cancer Discovery Award

Immune checkpoint therapy (ICT), which enhances immune responses against tumors, has shown dramatic results in lung cancer; however, only half of patients benefit from this therapy. ICT relies on ‘re-awakening’ T cell responses against tumors, but only about 50% of patients have evidence of such pre-existing responses. Adoptive cell transfer (ACT), involving the engineering of patients’ T cells to recognize tumors, allows for generation of therapeutic anti-tumor responses. ACT for lung cancer faces unique barriers to sustaining functional immune responses, as well as potential toxic effects from therapy. We will clarify the requirements for safe eradication of lung cancer by ACT using a mouse model of lung cancer that closely mimics human disease. We will also identify and develop strategies to overcome hurdles to effective T cell responses that must be addressed for translation into treatment strategies to benefit lung cancer patients.

No upcoming events near you